Dokument: The three-year evolution of Germany’s Digital Therapeutics reimbursement program and its path forward
| Titel: | The three-year evolution of Germany’s Digital Therapeutics reimbursement program and its path forward | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=68172 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20250120-122656-9 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Schmidt, Linea [Autor] Pawlitzki, Marc [Autor] Renard, Bernhard Y. [Autor] Meuth, Sven G. [Autor] Masanneck, Lars [Autor] | |||||||
| Dateien: |
| |||||||
| Beschreibung: | The 2019 German Digital Healthcare Act introduced the Digital Health Application program, known in German as ‘Digitale Gesundheitsanwendungen’ (DiGA). The program has established a pioneering model for integrating Digital Therapeutics (DTx) into a healthcare system with scalable and effective reimbursement strategies. To date, the continuous upward trend enabled by this framework has resulted in more than 374,000 DiGA prescriptions, increasingly cementing its role in the German healthcare system. This perspective provides a synthesis of the DiGA program’s evolution since its inception three years ago, highlighting trends regarding prescriptions and pricing as well as criticisms and identified shortcomings. It further discusses forthcoming legislative amendments, including the anticipated integration of higher-risk medical devices, which have the potential to significantly transform the program. Despite encountering challenges related to effectiveness, evidence requirements, and integration within the healthcare system, the DiGA program continues to evolve and serves as a seminal example for the integration of DTx, offering valuable insights for healthcare systems globally. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Schmidt, L., Pawlitzki, M., Renard, B. Y., Meuth, S., & Masanneck, L. (2024). The three-year evolution of Germany’s Digital Therapeutics reimbursement program and its path forward. Npj Digital Medicine, 7, Article 139. https://doi.org/10.1038/s41746-024-01137-1 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 20.01.2025 | |||||||
| Dateien geändert am: | 20.01.2025 |
